Inspire Medical Systems (INSP) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.29 per share a year ago.
Evaluate the expected performance of Inspire (INSP) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.
Inspire (INSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Inspire Medical Systems has shown impressive growth, become profitable and recently obtained FDA approval for a new device. The company's Inspire system treats sleep apnea with neurostimulation technology, achieving significant sales growth for years now. Trading at around 6 times sales, the company's strong performance, profitability, and growth potential make it an attractive investment.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Inspire (INSP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Inspire Medical (INSP) reports strong second-quarter results, reflecting a 30% revenue increase. Its new technology and expanded U.S. presence promise growth and enhanced patient care.
Inspire Medical Systems, Inc. (INSP) Q2 2024 Earnings Call Transcript
While the top- and bottom-line numbers for Inspire (INSP) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.